BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/06/2023 | 100% | Needham | → $12 | Reiterates | Buy → Buy |
09/25/2023 | 66.67% | RBC Capital | → $10 | Reiterates | Outperform → Outperform |
09/18/2023 | 66.67% | RBC Capital | $9 → $10 | Upgrades | Sector Perform → Outperform |
08/04/2023 | 50% | RBC Capital | $8 → $9 | Maintains | Sector Perform |
08/04/2023 | 83.33% | Jefferies | → $11 | Upgrades | Hold → Buy |
08/04/2023 | 400% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
08/03/2023 | 100% | Needham | $14 → $12 | Reiterates | → Buy |
07/13/2023 | 66.67% | B of A Securities | → $10 | Upgrades | Neutral → Buy |
05/04/2023 | 50% | RBC Capital | → $9 | Reiterates | → Sector Perform |
05/04/2023 | 133.33% | Needham | → $14 | Reiterates | → Buy |
04/20/2023 | 66.67% | Evercore ISI Group | $13 → $10 | Maintains | Outperform |
04/20/2023 | 133.33% | Needham | → $14 | Reiterates | → Buy |
03/14/2023 | 66.67% | RBC Capital | → $10 | Reiterates | → Sector Perform |
02/22/2023 | 166.67% | JMP Securities | → $16 | Reiterates | → Market Outperform |
02/22/2023 | 133.33% | Needham | → $14 | Upgrades | Hold → Buy |
02/22/2023 | 400% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
11/02/2022 | 166.67% | Evercore ISI Group | → $16 | Upgrades | In-Line → Outperform |
11/02/2022 | 116.67% | RBC Capital | $14 → $13 | Maintains | Sector Perform |
08/08/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
08/05/2022 | 133.33% | Barclays | $12 → $14 | Maintains | Equal-Weight |
08/05/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
08/05/2022 | 133.33% | Evercore ISI Group | → $14 | Downgrades | Outperform → In-Line |
04/18/2022 | 116.67% | Barclays | $22 → $13 | Downgrades | Overweight → Equal-Weight |
04/12/2022 | 133.33% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
04/11/2022 | 133.33% | B of A Securities | → $14 | Downgrades | Buy → Neutral |
04/11/2022 | 166.67% | Oppenheimer | $20 → $16 | Maintains | Outperform |
12/10/2021 | 166.67% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
11/04/2021 | 133.33% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
11/04/2021 | 183.33% | Barclays | $21 → $17 | Maintains | Overweight |
08/06/2021 | — | Jefferies | Downgrades | Buy → Hold | |
08/06/2021 | 166.67% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
08/06/2021 | 283.33% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
08/06/2021 | 250% | Barclays | $20 → $21 | Maintains | Overweight |
08/06/2021 | 400% | HC Wainwright & Co. | $18 → $30 | Maintains | Buy |
08/03/2021 | 250% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
03/24/2021 | 216.67% | HC Wainwright & Co. | $14 → $19 | Maintains | Buy |
01/22/2021 | 50% | RBC Capital | $7 → $9 | Maintains | Sector Perform |
12/07/2020 | 133.33% | HC Wainwright & Co. | $13 → $14 | Maintains | Buy |
11/24/2020 | 100% | Evercore ISI Group | → $12 | Initiates Coverage On | → Outperform |
06/17/2020 | — | BTIG | Initiates Coverage On | → Neutral | |
05/05/2020 | 16.67% | Barclays | $4 → $7 | Upgrades | Equal-Weight → Overweight |
11/15/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
05/24/2019 | -25% | RBC Capital | $16 → $4.5 | Downgrades | Outperform → Sector Perform |
04/02/2019 | 33.33% | Barclays | $6 → $8 | Maintains | Equal-Weight |
04/02/2019 | 200% | JMP Securities | $16 → $18 | Maintains | Market Outperform |
11/16/2018 | 150% | Piper Sandler | → $15 | Reinstates | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/06/2023 | 100% | 尼德姆 | → 12 美元 | 重申 | 購買 → 購買 |
09/25/2023 | 66.67% | 加拿大皇家銀行資本 | → 10 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
09/18/2023 | 66.67% | 加拿大皇家銀行資本 | 9 美元 → 10 美元 | 升級 | 行業表現 → 跑贏大盤 |
08/04/2023 | 50% | 加拿大皇家銀行資本 | 8 美元 → 9 美元 | 維護 | 行業表現 |
08/04/2023 | 83.33% | 傑富瑞集團 | → 11 美元 | 升級 | 持有 → 買入 |
08/04/2023 | 400% | HC Wainwright & Co. | → 30 美元 | 重申 | 購買 → 購買 |
08/03/2023 | 100% | 尼德姆 | 14 美元 → 12 美元 | 重申 | → 購買 |
07/13/2023 | 66.67% | B of A 類證券 | → 10 美元 | 升級 | 中性 → 買入 |
05/04/2023 | 50% | 加拿大皇家銀行資本 | → 9 美元 | 重申 | → 行業表現 |
05/04/2023 | 133.33% | 尼德姆 | → 14 美元 | 重申 | → 購買 |
04/20/2023 | 66.67% | Evercore ISI 集團 | 13 美元 → 10 美元 | 維護 | 跑贏大盤 |
04/20/2023 | 133.33% | 尼德姆 | → 14 美元 | 重申 | → 購買 |
03/14/2023 | 66.67% | 加拿大皇家銀行資本 | → 10 美元 | 重申 | → 行業表現 |
02/22/2023 | 166.67% | JMP 證券 | → 16 美元 | 重申 | → 市場跑贏大盤 |
02/22/2023 | 133.33% | 尼德姆 | → 14 美元 | 升級 | 持有 → 買入 |
02/22/2023 | 400% | HC Wainwright & Co. | → 30 美元 | 重申 | → 購買 |
11/02/2022 | 166.67% | Evercore ISI 集團 | → 16 美元 | 升級 | 盤中 → 跑贏大盤 |
11/02/2022 | 116.67% | 加拿大皇家銀行資本 | 14 美元 → 13 美元 | 維護 | 行業表現 |
08/08/2022 | — | 奧本海默 | 降級 | 跑贏大盤 → 表現 | |
08/05/2022 | 133.33% | 巴克萊 | 12 美元 → 14 美元 | 維護 | 重量相等 |
08/05/2022 | — | 奧本海默 | 降級 | 跑贏大盤 → 表現 | |
08/05/2022 | 133.33% | Evercore ISI 集團 | → 14 美元 | 降級 | 跑贏大盤 → 在線 |
04/18/2022 | 116.67% | 巴克萊 | 22 美元 → 13 美元 | 降級 | 超重 → 重量相等 |
04/12/2022 | 133.33% | 加拿大皇家銀行資本 | 16 美元 → 14 美元 | 維護 | 行業表現 |
2022 年 11 月 4 日 | 133.33% | B of A 類證券 | → 14 美元 | 降級 | 買入 → 中性 |
2022 年 11 月 4 日 | 166.67% | 奧本海默 | 20 美元 → 16 美元 | 維護 | 跑贏大盤 |
12/10/2021 | 166.67% | 奧本海默 | → 16 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2021 年 4 月 11 日 | 133.33% | 加拿大皇家銀行資本 | 16 美元 → 14 美元 | 維護 | 行業表現 |
2021 年 4 月 11 日 | 183.33% | 巴克萊 | 21 美元 → 17 美元 | 維護 | 超重 |
08/06/2021 | — | 傑富瑞集團 | 降級 | 買入 → 持有 | |
08/06/2021 | 166.67% | 加拿大皇家銀行資本 | 13 美元 → 16 美元 | 維護 | 行業表現 |
08/06/2021 | 283.33% | JMP 證券 | 22 美元 → 23 美元 | 維護 | 市場表現跑贏大盤 |
08/06/2021 | 250% | 巴克萊 | 20 美元 → 21 美元 | 維護 | 超重 |
08/06/2021 | 400% | HC Wainwright & Co. | 18 美元 → 30 美元 | 維護 | 買 |
08/03/2021 | 250% | 坎託·菲茨傑拉德 | → 21 美元 | 啓動覆蓋範圍開啓 | → 超重 |
2021 年 3 月 24 日 | 216.67% | HC Wainwright & Co. | 14 美元 → 19 美元 | 維護 | 買 |
2021 年 1 月 22 日 | 50% | 加拿大皇家銀行資本 | 7 美元 → 9 美元 | 維護 | 行業表現 |
12/07/2020 | 133.33% | HC Wainwright & Co. | 13 美元 → 14 美元 | 維護 | 買 |
11/24/2020 | 100% | Evercore ISI 集團 | → 12 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2020 年 6 月 17 日 | — | BTIG | 啓動覆蓋範圍開啓 | → 中立 | |
05/05/2020 | 16.67% | 巴克萊 | 4 美元 → 7 美元 | 升級 | 重量相等 → 超重 |
11/15/2019 | — | B of A 類證券 | 升級 | 中性 → 買入 | |
05/24/2019 | -25% | 加拿大皇家銀行資本 | 16 美元 → 4.5 美元 | 降級 | 跑贏大盤 → 行業表現 |
04/02/2019 | 33.33% | 巴克萊 | 6 美元 → 8 美元 | 維護 | 重量相等 |
04/02/2019 | 200% | JMP 證券 | 16 美元 → 18 美元 | 維護 | 市場表現跑贏大盤 |
11/16/2018 | 150% | 派珀·桑德勒 | → 15 美元 | 恢復 | → 超重 |
What is the target price for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的目標價格是多少?
The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by Needham on November 6, 2023. The analyst firm set a price target for $12.00 expecting BCRX to rise to within 12 months (a possible 100.00% upside). 16 analyst firms have reported ratings in the last year.
Needham於2023年11月6日公佈了BioCryst Pharma(納斯達克股票代碼:BCRX)的最新目標股價。該分析公司將目標股價定爲12美元,預計BCRX將在12個月內升至12個月內(可能上漲100.00%)。去年有16家分析公司公佈了評級。
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
分析師對BioCryst Pharma(BCRX)的最新評級是多少?
The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by Needham, and BioCryst Pharma reiterated their buy rating.
BioCryst Pharma(納斯達克股票代碼:BCRX)的最新分析師評級由Needham提供,BioCryst Pharma重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
BioCryst Pharma(BCRX)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與BioCryst Pharma的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。BioCryst Pharma的最新評級是在2023年11月6日公佈的,因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
分析師對 BioCryst Pharma (BCRX) 的評級正確嗎?
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioCryst Pharma (BCRX) is trading at is $6.00, which is within the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但重申了最新的BioCryst Pharma(BCRX)評級,目標股價爲0.00美元至12.00美元。BioCryst Pharma(BCRX)的當前交易價格爲6.00美元,在分析師的預測區間內。